S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NASDAQ:PODD

Insulet Stock Forecast, Price & News

$289.20
-1.40 (-0.48 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$287.00
$291.69
50-Day Range
$263.67
$307.27
52-Week Range
$214.21
$309.99
Volume177,531 shs
Average Volume453,356 shs
Market Capitalization$19.92 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67
30 days | 90 days | 365 days | Advanced Chart
Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.


Insulet logo

About Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

496th out of 1,351 stocks

Surgical & Medical Instruments Industry

48th out of 123 stocks

Analyst Opinion: 1.3Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

What stocks does MarketBeat like better than Insulet?

Wall Street analysts have given Insulet a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Insulet wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its earnings results on Thursday, August, 5th. The medical instruments supplier reported $0.10 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.12 by $0.02. The medical instruments supplier earned $263.20 million during the quarter, compared to analysts' expectations of $257.80 million. Insulet had a positive trailing twelve-month return on equity of 0.21% and a negative net margin of 3.06%.
View Insulet's earnings history
.

How has Insulet's stock been impacted by Coronavirus?

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PODD shares have increased by 68.0% and is now trading at $289.20.
View which stocks have been most impacted by COVID-19
.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.05 billion-$1.09 billion, compared to the consensus revenue estimate of $1.08 billion.

What price target have analysts set for PODD?

13 brokers have issued 12 month price objectives for Insulet's shares. Their forecasts range from $245.00 to $325.00. On average, they anticipate Insulet's share price to reach $283.50 in the next year. This suggests that the stock has a possible downside of 2.0%.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Shacey Petrovic, President, Chief Executive Officer & Director
  • Charles Alpuche, Chief Operations Officer & Executive VP
  • Wayde Dwight McMillan, Chief Financial Officer, Treasurer & Executive VP
  • Trang Ly, Senior Vice President & Medical Director
  • Michael P. Spears, Senior VP-Quality, Regulatory Affairs & Compliance

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.57%), Primecap Management Co. CA (2.22%), Geode Capital Management LLC (1.20%), Clearbridge Investments LLC (1.19%), William Blair Investment Management LLC (1.13%) and Coatue Management LLC (0.86%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which major investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Coatue Management LLC, MUFG Securities EMEA plc, Lord Abbett & CO. LLC, Jennison Associates LLC, Westfield Capital Management Co. LP, Natixis, Millennium Management LLC, and Bellevue Group AG. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, John A Fallon, Sally Crawford, and Shacey Petrovic.
View insider buying and selling activity for Insulet
or view top insider-selling stocks.

Which major investors are buying Insulet stock?

PODD stock was purchased by a variety of institutional investors in the last quarter, including Amundi, UBS Asset Management Americas Inc., Bridgewater Associates LP, Cubist Systematic Strategies LLC, SG Americas Securities LLC, Skandinaviska Enskilda Banken AB publ, Geode Capital Management LLC, and AMF Pensionsforsakring AB.
View insider buying and selling activity for Insulet
or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $289.20.

How much money does Insulet make?

Insulet has a market capitalization of $19.92 billion and generates $904.40 million in revenue each year. The medical instruments supplier earns $6.80 million in net income (profit) each year or $0.10 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 1,900 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

Where are Insulet's headquarters?

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at (978) 600-7000 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.